The Journal of Immunology, Vol 143, Issue 5 1555-1559, Copyright © 1989 by American Association of Immunologists

ARTICLES

Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes

AR Hayward and M Shreiber
Department of Pediatrics, University of Colorado School of Medicine, Denver 80262.

Over 80% of nonobese diabetic (NOD) mice develop lymphocytic infiltrates of their pancreatic islets (insulitis) by 6 wk of age and 50% of the females are diabetic by 6 mo of age. The incidence of insulitis in NOD mice injected once as neonates with 250 micrograms of the CD3 antibody, 145.2C11, was 8% at 10 wk of age, increasing to 25% at 32 wk of age. Fewer than 10% of these animals developed diabetes by 8 mo of age. Neonatal administration of 145.2C11 reduced the proliferative responses of spleen cells to mitogen stimulation 2 and 4 wk postinjection and expression of TCR was reduced 1 to 5 wk postinjection. The percentage of CD4 and CD8 cells in the spleen was transiently reduced after injection and the frequency of Pgp-1+-high cells (putative memory cells) was increased 2 to 4 wk postinjection, suggesting that in vivo administration of the antibody caused some T cells to divide as well as transiently reducing T cell numbers. IL-2R expression was not detected on spleen cells in the 4 wk after antibody injection. The phenotypic and functional changes after neonatal CD3 antibody injection resolved by 8 wk of age. The control and injected mice grew normally and made equivalent IgG antibody responses to injected human IgG. Neonatally injected 145.2C11 antibody was cleared from the circulation with a terminal half-life approximating to 21 days but greater than 90% of antigen binding activity was lost 6 days after injection. Protection from diabetes did not follow neonatal elimination of T cells with CD4 and CD8 antibodies, nor the injection of a TCR subset antibody, F23.1. Our data suggest that the neonatal T cell repertoire is open to modulation by a single injection of a CD3 antibody and they offer a new experimental approach to immunotherapy in an animal model of type 1 diabetes.

This article has been cited by other articles:

				D. L YOUNG, S. RAMANUJAN, H. T.C KREUWEL, C. C. WHITING, K. G GADKAR, and L. K.M SHODA Mechanisms Mediating Anti-CD3 Antibody Efficacy: Insights from a Mathematical Model of Type 1 Diabetes Ann. N.Y. Acad. Sci., October 1, 2006; 1079(1): 369 - 373. [Abstract] [Full Text] [PDF]

				A. P. Kohm, J. S. Williams, A. L. Bickford, J. S. McMahon, L. Chatenoud, J.-F. Bach, J. A. Bluestone, and S. D. Miller Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis J. Immunol., April 15, 2005; 174(8): 4525 - 4534. [Abstract] [Full Text] [PDF]

				S. You, G. Slehoffer, S. Barriot, J.-F. Bach, and L. Chatenoud Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice PNAS, October 5, 2004; 101(suppl_2): 14580 - 14585. [Abstract] [Full Text] [PDF]

				J.-W. Yoon and H.-S. Jun Cellular and Molecular Pathogenic Mechanisms of Insulin-Dependent Diabetes Mellitus Ann. N.Y. Acad. Sci., April 1, 2001; 928(1): 200 - 211. [Abstract] [Full Text] [PDF]

				V. Judkowski, C. Pinilla, K. Schroder, L. Tucker, N. Sarvetnick, and D. B. Wilson Identification of MHC Class II-Restricted Peptide Ligands, Including a Glutamic Acid Decarboxylase 65 Sequence, that Stimulate Diabetogenic T Cells from Transgenic BDC2.5 Nonobese Diabetic Mice J. Immunol., January 15, 2001; 166(2): 908 - 917. [Abstract] [Full Text] [PDF]

				K. Lejon C. and G. Fathman Isolation of Self Antigen-Reactive Cells from Inflamed Islets of Nonobese Diabetic Mice Using CD4high Expression as a Marker J. Immunol., November 15, 1999; 163(10): 5708 - 5714. [Abstract] [Full Text] [PDF]

				A. Herbelin, J.-M. Gombert, F. Lepault, J.-F. Bach, and L. Chatenoud Mature Mainstream TCR{alpha}{beta}+CD4+ Thymocytes Expressing L-Selectin Mediate ""Active Tolerance"" in the Nonobese Diabetic Mouse J. Immunol., September 1, 1998; 161(5): 2620 - 2628. [Abstract] [Full Text] [PDF]